Benzoxazines are a type of heterocyclic compounds consisting of benzene and oxazine rings. Benzoxazine research is developing rapidly because of the many potential applications of the materials.
Sensorion announced it has met the primary endpoint for its Proof of Concept (POC) Phase 2a clinical trial of SENS-401 for residual hearing preservation following cochlear implantation. SENS-401 is a first-in-class drug candidate to treat Sudden Sensorineural Hearing Loss (SSNHL). It is aiming at treating or protecting against inner ear lesions that lead to nerve degeneration and sensory hair cell loss.